Fate of Immunex's $1-Bil Seattle Portfolio Not Fully Decided

SEATTLE, WA-Included in the most pricey bio-tech acquisition ever–Amgen’s $16-billion acquisition of Seattle-based Immunex Corp–is nearly $1 billion in Puget Sound real estate and another $1 billion in Rhode Island factories. While Amgen has made pledges to keep some of the properties acquired in the transaction, including the $750 million project on Seattle’s waterfront, continued ownership of a 150,000-sf facility in Bothell is yet to be determined.

GlobeSt.com discussed the real estate aspects of the acquisition with Rebecca Hamm, a spokesperson with Amgen, headquartered in Thousand Oaks, CA. GlobeSt.com was unable to reach Immunex officials for comment, as its executive offices are closed until after New Year’s Day.

Hamm confirms that after closing sometime in late 2002, the company plans to retain both Immunex’s Rhode Island factories and the $750-million Helix Project, a new headquarters campus under construction at Terminal 88 in Seattle’s Interbay area.